Early molecular and genetic determinants of primary liver malignancy

Surgical Clinics of North America

Volumn 84, Issue 2, 2004, Pages 339-354

  Feitelson, Mark A ^a   Pan, Jingbo ^a   Lian, Zhaorui ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; MATRIX METALLOPROTEINASE;

ANTIGEN BINDING; ANTIGEN FUNCTION; CANCER SUSCEPTIBILITY; CARCINOGENESIS; DNA MICROARRAY; GENE DELETION; GENE MUTATION; GENE REARRANGEMENT; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HEPATITIS B; HEPATITIS B VIRUS; HETEROZYGOSITY LOSS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR GENETICS; MOLECULAR INTERACTION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DNA DAMAGE; DNA, VIRAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS B ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; LOSS OF HETEROZYGOSITY; MATRIX METALLOPROTEINASES; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; UP-REGULATION;

EID: 1642375342     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6109(03)00226-3     Document Type: Review

References (118)

1. Feitelson M.A. Hepatitis B virus and cancer. Notkins A.L., Oldstone M.B.A. Concepts in viral pathogenesis II. 1986;269-275 Springer-Verlag, New York.
2. Nalpas B., Feitelson M.A., Brechot C., Rubin E. Alcohol, hepatotropic viruses and hepatocellular carcinoma. Alcohol. 19:1995;1089-1095.
3. LaBrecque D.R. Neoplasia and the liver. Kaplowitz N. Liver and biliary diseases. 1992;347-388 Williams & Wilkins, Baltimore (MD).
4. Chen C.J., Yu M.W., Liaw Y.F. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol. 12:1997;S294-S308.
5. Beasley R.P., Hwang L.Y. Epidemiology of hepatocellular carcinoma. Vyas G.N., Dienstag J.L., Hoofnagle J.H. Viral hepatitis and liver disease. 1984;209-224 Grune & Stratton, Inc. New York.
6. Kim S.O., Park J.G., Lee I.K. Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene activation by hepatitis B virus X gene product. Cancer Res. 56:1996;3831-3836.
7. Murakami Y., Hayashi K., Hirohashi S., Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res. 51:1991;5520-5525.
8. Nishida N., Fukuda Y., Komeda T., Kita R., Sando T., Furukawa M., et al. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res. 54:1994;3107-3110.
9. Peng S.Y., Lai P.L., Hsu M.C. Amplification of the c-myc gene in human hepatocellular carcinoma: biologic significance. J Formos Med Assoc. 92:1993;866-870.
10. Boige V., Laurent-Puig P., Fouchet P., Flejou J.F., Monges G., Bedossa P., et al. Concerted nonsyntenic allelic losses in hyperploid hepatocellular carcinoma as determined by a high-resolution allelotype. Cancer Res. 57:1997;1986-1990.
11. Marchio A., Meddeb M., Pineau P., Danglot G., Tiollais P., Bernheim A. Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer. 18:1997;59-65.
12. Lencioni R., Caramella D., Bartolozzi C., Di Coscio G. Long-term follow-up study of adenomatous hyperplasia in liver cirrhosis. Ital J Gastroenterol. 26:1994;163-168.
13. Santoni-Rugiu E., Nagy P., Jensen M.R., Factor V.M., Thorgeirsson S.S. Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-α Am J Pathol. 149:1996;407-428.
14. Sargent L.M., Sanderson S.D., Thorgeirsson S.S. Ploidy and karyotype alterations associated with early events in the development of hepatocarcinogenesis in transgenic mice harboring c-myc and transforming growth factor α transgenes. Cancer Res. 56:1996;2137-2142.
15. Nakau M., Miyoshi H., Seldin M.F., Imamura M., Oshima M., Taketo M.M. Hepatocellular carcinoma caused by loss of heterozygosity in Lkb1 gene knockout mice. Cancer Res. 62:2002;4549-4553.
16. Ueda H., Ullrich S.J., Gangemi J.D., Kappel C.A., Ngo L., Feitelson M.A., et al. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet. 9:1995;41-47.
17. Factor V.M., Kao C.Y., Santoni-Rugiu E., Woitach J.T., Jensen M.R., Thorgeirsson S.S. Constitutive expression of mature transforming growth factor beta1 in the liver accelerates hepatocarcinogenesis in transgenic mice. Cancer Res. 57:1997;2089-2095.
18. Murakami H., Sanderson N.D., Nagy P., Marino P.A., Merlino G., Thorgeirsson S.S. Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res. 53:1993;1719-1723.
19. Collier J., Sherman M. Screening for hepatocellular carcinoma. Hepatology. 27:1998;273-278.
20. Chang M.H., Chen D.S., Hsu H.C., Hsu H.Y., Lee C.Y. Maternal transmission of hepatitis B virus in childhood hepatocellular carcinoma. Cancer. 64:1989;2377-2380.
21. Simbulan-Rosenthal C.M., Haddad B.R., Rosenthal D.S., Weaver Z., Coleman A., Luo R., et al. Chromosomal aberrations in PARP(-/-) mice: genome stabilization in immortalized cells by reintroduction of poly(ADP-ribose) polymerase cDNA. Proc Natl Acad Sci U S A. 96:1999;13191-13196.
22. Tong W.M., Cortes U., Hande M.P., Ohgaki H., Cavalli L.R., Lansdorp P.M., et al. Synergistic role of Ku80 and poly(ADP-ribose) polymerase in suppressing chromosomal aberrations and liver cancer formation. Cancer Res. 62:2002;6990-6996.
23. Werner M., Nolte M., Georgii A., Klempnuaer J. Chromosome 1 abnormalities in hepatocellular carcinoma. Cancer Genet Cytogenet. 66:1993;130.
24. Nagai H., Pineau P., Tiollais P., Buendia M.A., Dejean A. Comprehensive allotyping of human hepatocellular carcinoma. Oncogene. 14:1997;2927-2933.
25. Chernet B.W., McBride O.W., Chen D., Alkhatib H., Bhatia K.G., Hensley P., et al. cDNA sequence, protein structure, and chromosomal location of human gene for poly(ADP-ribose)polymerase. Proc Natl Acad Sci U S A. 84:1987;8370-8374.
26. Blunt T., Tacciioli G.E., Priestley A., Hafezparast M., McMillan T., Liu J., et al. A YAC contig encompassing the XRCC5 (Ku80) DNA repair gene and complementation defective cells by YAC protoplast fusion. Genomics. 30:1995;320-328.
27. Giardiello F.M., Welsh S.B., Hamilton S.R., Offerhaus G.J.A., Gittelsohn A.M., Booker S.V., et al. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med. 316:1987;1511-1514.
28. Tiainen M., Ylikorkala A., Makela T.P. Growth suppression by Lkb1 is mediated by a G1 cell cycle arrest. Proc Natl Acad Sci U S A. 96:1999;9248-9251.
29. Ylikorkala A., Rossi D.J., Korsisaari N., Luukko K., Alitalo K., Henkemeyer M., et al. Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice. Science. 293:2001;1323-1326.
30. Feitelson M.A., Duan X.L. Hepatitis B virus x antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma. Am J Pathol. 150:1997;1141-1157.
31. Feitelson M.A. Hepatitis B virus in hepatocarcinogenesis. J Cell Physiol. 181:1999;188-202.
32. Lee T., Elledge S.J., Butel J.S. Hepatitis B virus X protein interacts with a probably cellular DNA repair protein. J Virol. 69:1995;1107-1114.
33. Becker S.A., Lee T.H., Butel J.S., Slagle B.L. Hepatitis B virus X protein interfers with cellular DNA repair. J Virol. 72:1998;266-272.
34. Hwang B.J., Liao J.C., Chu G. Isolation of a cDNA encoding a UV-damaged DNA binding factor defective in xeroderma pigmentosum group E cells. Mutat Res. 362:1996;105-117.
35. Kazantsev A., Mu D., Nichols A.F., Zhao X., Linn S., Sancar A. Functional complementation of xeroderma pigmentosum complementation group E by replication protein A in an in vitro system. Proc Natl Acad Sci U S A. 93:1996;5014-5018.
36. Feitelson M.A., Zhu M., Duan L.X., London W.T. Hepatitis B X antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene. 8:1993;1109-1117.
37. Wang X.W., Forrester K., Yeh H., Feitelson M.A., Gu J.R., Harris C.C. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci U S A. 91:1994;2230-2234.
38. Bootsma D., Hoeijmakers J.H.J. Engagement with transcription. Nature. 363:1993;114-115.
39. Schaeffer L., Roy R., Humbert S., Moncollin V., Vermeulen W., Hoeijmakers J.H.J., et al. DNA repair helicase: A component of BTF2 (TFIIH) basic transcription factor. Science. 260:1993;58-63.
40. Madden C.R., Fingegold M.J., Slagle B.L. Expression of hepatitis B x protein does not alter the accumulation of spontaneous mutations in transgenic mice. J Virol. 74:2000;5266-5272.
41. Feitelson M.A. Hepatocellular injury in hepatitis B and C infections. Feitelson M.A., Zern M. Clinics in laboratory medicine. vol. 16, no. 2:1996;307-324 WB Saunders Co. Philadelphia.
42. Dunsford H.A., Sell S., Chisari F.V. Hepatocarcinogenesis due to chronic liver cell injury in HBV transgenic mice. Cancer Res. 50:1990;3400-3407.
43. Hagen T.M., Suang S., Curnutte J., Fowler P., Martinez V., Wehr C.M., et al. Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc Natl Acad Sci U S A. 91:1994;12808-12812.
44. Guyton K.Z., Kensler T.W. Oxidative mechanisms in carcinogenesis. Br Med Bull. 49:1993;523-544.
45. Ohsima H., Bartsch H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res. 305:1994;253-264.
46. t: activation of NF-κB, selective inhibition by antioxidants and integral membrane localization. EMBO J. 11:1992;2991-3001.
47. Hino O., Tabata S., Hotta Y. Evidence for increased in vitro recombination with insertion of human hepatitis B virus DNA. Proc Natl Acad Sci U S A. 88:1991;9248-9252.
48. Livezey K.W., Simon D. Accumulation of genetic alterations in a human hepatoma cell line transfected with hepatitis B virus. Mutat Res. 377:1997;187-198.
49. Laurent-Puig P., Legoix P., Bluteau O., Belghiti J., Franco D., Binot F., et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology. 120:2001;1763-1773.
50. Wang J., Chenivesse X., Henglein B., Brechot C. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature. 343:1990;555-557.
51. Benbrook D., Lernhardt E., Pfahl M. A new retinoic acid receptor identified from a hepatocellular carcinoma. Nature. 333:1988;669-672.
52. Gozuacik D., Mrakami Y., Saigo K., Chami M., Mugnier C., Lagorce D., et al. Identification of human cancer-related genes by naturally occurring Hepatitis B Virus DNA tagging. Oncogene. 20:2001;6233-6240.
53. Dejean A., de The H. Hepatitis B virus as an insertional mutagene in a human hepatocellular carcinoma. Mol Biol Med. 7:1990;213-222.
54. Dejean A., Sonigo P., Wain-Hobson S., Tiollais P. Specific hepatitis B virus integration in hepatocellular carcinoma DNA through a viral 11-base-pair direct repeat. Proc Natl Acad Sci U S A. 81:1984;5350-5354.
55. Diamantis I.D., McGandy C.E., Chen T.J., Liaw Y.F., Gudat F., Bianchi L. Hepatitis B X-gene expression in hepatocellular carcinoma. J Hepatol. 15:1992;400-403.
56. Paterlini P., Poussin K., Kew M., Franco D., Brechot C. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology. 21:1995;313-321.
57. Haruna Y., Hayashi N., Katayama K., Yuki N., Kasahara A., Sasaki Y., et al. Expression of X protein and hepatitis B virus replication in chronic hepatitis. Hepatology. 13:1991;417-421.
58. Wang W., London W.T., Feitelson M.A. Hepatitis B x antigen in hepatitis B virus carrier patients with liver cancer. Cancer Res. 51:1991;4971-4977.
59. Wang W., London W.T., Lega L., Feitelson M.A. Hepatitis B x antigen in liver from carrier patients with chronic hepatitis and cirrhosis. Hepatology. 14:1991;29-37.
60. Poussin K., Kienes H., Sirma H., Urban S., Beaugrand M., Franco D., et al. Expression of mutated hepatitis B virus X genes in human hepatocellular carcinomas. Int J Cancer. 80:1999;497-505.
61. Elmore L., Hancock A.R., Chang S.F., Wang X.W., Chang S., Callahan C.P., et al. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci U S A. 94:1997;14707-14712.
62. Kim H., Lee H., Yun Y. X-gene product of hepatitis B virus induces apoptosis in liver cells. J Biol Chem. 273:1998;381-385.
63. Sirma H., Giannini C., Poussin K., Paterlini P., Kremsdorf D., Brechot C. Genetic and functional analysis of the effects of hepatitis B viral transactivator HBx on cell growth and apoptosis: implications for viral replication and hepatocarcinogenesis. Fleig W.E. Normal and malignant liver cell growth: FALK workshop. 1999;171-186 Kluwer Academic Publishers, Norwell (MA).
64. Tu H., Bonura C., Giannini C., Mouly H., Soussan P., Kew M., et al. Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res. 61:2001;7803-7810.
65. Huo T.I., Wang X.W., Forgues M., Wu C.G., Spillare E.A., Giannini C., et al. Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis. Oncogene. 20:2001;3620-3628.
66. Feitelson M.A., Reis H., Pan J., Lian Z., Fang J., Liu J., et al. Abrogation of negative growth regulatory pathways by hepatitis B virus encoded X antigen in the development of hepatocellular carcinoma. Fleig W.E. Normal and malignant liver cell growth: FALK workshop. 1999;156-170 Kluwer Academic Publishers, Norwell (MA).
67. Sun B.S., Zhu X., Clayton M.M., Pan J., Feitelson M.A. Identification and preliminary characterization of a protein involved in cellular senescence which binds to hepatitis B virus X antigen. Hepatology. 27:1998;228-239.
68. D'Arville C.N., Nouri-Aria K.T., Johnson P., Williams R. Regulation of insulin-like growth factor II gene expression by hepatitis B virus in hepatocellular carcinoma. Hepatology. 13:1991;310-315.
69. Aihara T., Noguchi S., Miyoshi Y., Nakano H., Sasaki Y., Nakamura Y., et al. Allelic imbalance of insulin-like growth factor II gene expression in cancerous and precancerous lesions of the liver. Hepatology. 28:1998;86-89.
70. Benn J., Schneider R.J. HBV X protein activates ras-GTP complex formation and establishes a ras, raf, MAP kinase signaling cascade. Proc Natl Acad Sci U S A. 91:1994;10350-10354.
71. Lucito R., Schneider R.J. Hepatitis B virus X protein activates transcription factor NF-kappa B without a requirement for protein kinase C. J Virol. 66:1992;983-991.
72. Shirota Y., Keneko S., Honda M., Kawai H.F., Kobayashi K. Identification of differentially expressed genes in hepatocellular carcinoma with cDNA microarrays. Hepatology. 33:2001;832-840.
73. Lian Z., Liu J., Pan J., Tufan N.L.S., Zhu M., Arbuthnot P., et al. A cellular gene up-regulated by hepatitis B virus encoded X antigen promotes hepatocellular growth and survival. Hepatology. 34:2001;146-157.
74. Tufan N.L.S., Lian Z., Liu J., Pan J., Arbuthnot P., Kew M., et al. Hepatitis B x antigen stimulates expression of a novel cellular gene, URG4, that promotes hepatocellular growth and survival. Neoplasia. 4:2002;355-368.
75. Lian Z., Liu J., Li L., Li X., Tufan N.L.S., Clayton M.M., et al. Up-regulated expression of a unique gene by hepatitis B x antigen promotes hepatocellular growth and tumorigenesis. Neoplasia. 5:2003;229-244.
76. Yoo Y.D., Ueda H., Park K., Flanders K.C., Lee Y.I., Jay G., et al. Regulation of transforming growth factor-beta 1 expression by the hepatitis B virus (HBV) X transactivator. Role in HBV pathogenesis. J Clin Invest. 97:1996;388-395.
77. Rossmanith W., Schulte-Hermann R. Biology of transforming growth factor beta in hepatocarcinogenesis. Microsc Res Tech. 52:2001;430-436.
78. Giannelli G., Fransvea E., Marinosci F., Bergamini C., Colucci S., Schiraldi O., et al. Transforming growth factor-β1 triggers hepatocellular carcinoma invasiveness via α3β1 integrin. Am J Pathol. 161:2002;183-193.
79. Okabe H., Satoh S., Kato T., Kitahara O., Yanagawa R., Yamaoka Y., et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res. 61:2001;2129-2137.
80. Xu X.R., Huang J., Xu Z.G., Qian B.Z., Zhu Z.D., Yan Q., et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding nontumor liver. Proc Natl Acad Sci U S A. 98:2001;15089-15094.
81. Chen X., Cheung S.T., So S., Fan S.T., Barry C., Higgins J., et al. Gene expression patterns in human liver cancers. Mol Biol Cell. 13:2002;1929-1939.
82. Benn J., Schneider R.J. Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls. Proc Natl Acad Sci U S A. 92:1995;11215-11219.
83. Lian Z., Pan J., Liu J., Zhu M., Arbuthnot P., Kew M.C., et al. The translation initiation factor, SUI1, may be a target of hepatitis B x antigen in hepatocarcinogenesis. Oncogene. 18:1999;1677-1687.
84. Kim M.Y., Park E., Park J.H., Park D.H., Moon W.S., Cho B.H., et al. Expression profile of none novel gene differentially expressed in hepatitis B virus-associated hepatocellular carcinomas. Oncogene. 20:2001;4568-4575.
85. Cheung S.T., Chen X., Guan X.Y., Wong S.Y., Tai L.S., Ng I.O.L., et al. Identify metastasis-associated genes in hepatocellular carcinoma through clonality delineation for multinodular tumor. Cancer Res. 62:2002;4711-4721.
86. Calvisi D.F., Factor V.M., Loi R., Thorgeirsson S.S. Activation of beta-catenin during hepatocarcinogenesis in transgenic mouse models: relationship to phenotype and tumor grade. Cancer Res. 61:2001;2085-2091.
87. Xu L., Hui L., Wang S., Gong J., Jin Y., Wang Y., et al. Expression profiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma. Cancer Res. 61:2001;3176-3181.
88. De La Costa A., Romagnolo B., Billuart P., Renard C.A., Buendia M.A., Soubrane O., et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A. 95:1998;8847-8851.
89. Hsu H.C., Jeng Y.M., Mao T.L., Chu J.S., Lai P.L., Peng S.Y. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol. 157:2000;763-770.
90. Miyoshi Y., Iwao K., Nagasawa Y., Aihara T., Sasaki Y., Imaoka S., et al. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res. 58:1998;2524-2527.
91. Mao T.L., Chu J.S., Jeng Y.M., Lai P.L., Hsu H.C. Expression of mutant nuclear beta-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis. J Pathol. 193:2001;95-101.
92. Cadoret A., Ovejero C., Saadi-Kheddouci S., Souil E., Fabre M., Romagnolo B., et al. Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin. Cancer Res. 61:2001;3245-3249.
93. Huang J., Kwong J., Sun E.C.Y., Liang T.J. Proteasome complex as a potential cellular target of hepatitis B virus X protein. J Virol. 70:1996;5582-5591.
94. Hu Z., Zhang Z., Doo E., Coux O., Goldberg A.L., Liang T.J. Hepatitis B virus X protein is both a substrate and a potential inhibitor of the proteasome complex. J Virol. 73:1999;7231-7240.
95. Zhang Z., Torii N., Furusaka A., Malayaman N., Hu Z., Liang T.J. Structural and functional characterization of interaction between hepatitis B virus X protein and the proteasome complex. J Biol Chem. 275:2000;15157-15165.
96. Okazaki I., Wada N., Nakano M., Saito A., Takasaki K., Doi M., et al. Difference in gene expression for matrix metalloproteinase-1 between early and advanced hepatocellular carcinomas. Hepatology. 25:1997;580-584.
97. Ozaki I., Mizuta T., Zhao G., Yotsumoto H., Hara T., Kajihara S., et al. Involvement of the Ets-1 gene in over-expression of matrilysin in human hepatocellular carcinoma. Cancer Res. 60:2000;6519-6525.
98. Park U.S., Park S.K., Lee Y.I., Park J.G., Lee Y.I. Hepatitis B virus-X protein upregulates the expression of p21waf1/cip1 and prolongs G1→S transition via a p53-independent pathway in human hepatoma cells. Oncogene. 19:2000;3384-3394.
99. Kuroki T., Fujiwara Y., Tsuchiya E., Nakamori S., Imaoka S., Kanematsu T., et al. Accumulation of genetic changes during development and progression of hepatocellular carcinoma: loss of heterozygosity of chromosome arm 1p occurs at an early stage of hepatocarcinogenesis. Genes Chromosomes Cancer. 13:1995;163-167.
100. Konishi M., Kikuchi-Yanoshita R., Tanaka K., Sato C., Tsuruta K., Maeda Y., et al. Genetic changes and histopathological grades in human hepatocellular carcinomas. Jpn J Cancer Res. 84:1993;893-899.
101. Niketeghad F., Decker H.J., Caselmann W.H., Lund P., Geissler F., Dienes H.P., et al. Frequent genomic imbalances suggest commonly altered tumour genes in human hepatocarcinogenesis. Br J Cancer. 85:2001;697-704.
102. Yeh S.H., Chen P.J., Shau W.Y., Chen Y.W., Lee P.H., Chen J.T., et al. Chromosomal allelic imbalance evolving from liver cirrhosis to hepatocellular carcinoma. Gastroenterology. 121:2001;699-709.
103. DeSouze A.T., Hankins G.R., Washington M.K., Fine R.L., Orton T.C., Jirtle R.L. Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene. 10:1995;1725-1729.
104. Kishimoto Y., Shiota G., Wada K., Kitano M., Nakamoto K., Kamisaki Y., et al. Frequent loss in chromosome 8p loci in liver cirrhosis accompanying hepatocellular carcinoma. J Cancer Res Clin Oncol. 122:1996;585-589.
105. Huang S.F., Hsu H.C., Fletcher J.A. Investigation of chromosomal aberrations in hepatocellular carcinoma by fluorescence in situ hybridization. Cancer Genet Cytogenet. 111:1999;21-27.
106. Knuutila S., Aalto Y., Autio K., Bjorkqvist A.M., El-Rifai W., Hemmer S., et al. DNA copy number losses in human neoplasms. Am J Pathol. 155:1999;683-694.
107. Peng C.Y., Tsai S.L., Yeh C.T., Hung S.P., Chen M.F., Chen T.C., et al. Genetic alternations of p73 are infrequent but may occur in early stage hepatocellular carcinoma. Anticancer Res. 20:2000;1487-1492.
108. Tannapfel A., Wasner M., Krause K., Geissler F., Katalinic A., Hauss J., et al. Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst. 91:1999;1154-1158.
109. Sun M., Eshleman J.R., Ferrell L.D., Jacobs G., Sudilovsky E.C., Tuthill R., et al. An early lesion in hepatic carcinogenesis: loss of heterozygosity in human cirrhotic livers and dysplastic nodules at the 1p36-p34 region. Hepatology. 33:2001;1415-1424.
110. Fang W., Piao Z., Simon D., Sheu J.C., Huang S. Mapping of a minimal deleted region in human hepatocellular carcinoma to 1p36.13-p36.23 and mutational analysis of the RIZ (PRDM2) gene localized to the region. Genes Chromsomes Cancer. 28:2000;269-275.
111. Kawate S., Takenoshita S., Ohwada S., Mogi A., Fukusato T., Makita F., et al. Mutation analysis of transforming growth factor beta type II receptor, Smad2, and Smad4 in hepatocellular carcinoma. Int J Oncol. 14:1999;127-131.
112. Wada I., Kanada H., Nomura K., Kato Y., Machinami R., Kitagawa T. Failure to detect genetic alteration of the mannose-6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) gene in hepatocellular carcinomas in Japan. Hepatology. 29:1999;1718-1721.
113. Yuan B.Z., Miller M.J., Keck C.L., Zimonjic D.B., Thorgeirsson S.S., Popescu N.C. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res. 58:1998;2196-2199.
114. Piao Z., Kim N.G., Kim H., Park C. Deletion mapping on the short arm of chromosome 8 in hepatocellular carcinoma. Identification of three distinct regions of allelic deletions on the short arm of chromosome 8 in hepatocellular carcinoma. Cancer Lett. 138:1999;227-232.
115. Pineau P., Nagai H., Prigent S., Wei Y., Gyapay G., Weissenbach J., et al. Identification of three distinct regions of allelic deletions on the short arm of chromosome 8 in hepatocellular carcinoma. Oncogene. 18:1999;3127-3134.
116. Gupta S. Hepatic polyploidy and liver growth control. Semin Cancer Biol. 10:2000;161-171.
117. Wong N., Lai P., Pang E., Fung L.F., Sheng Z., Wong V., et al. Genomic aberrations in human hepatocellular carcinomas of differing etiologies. Clin Cancer Res. 6:2000;4000-4009.
118. Wu T.C., Tong M.J., Hwang B., Lee S.D., Hu M.M. Primary hepatocellular carcinoma and hepatitis B virus infection during childhood. Hepatology. 7:1987;46-48.